Effect of adolescent exposure to WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 1, 2010, Pages 166-171

  Rodríguez Arias, Marta ^a   Manzanedo, Carmen ^a   Roger Sánchez, Concepción ^a   Couto, Bruno Ribeiro Do ^b   Aguilar, María Asunción ^a   Miñarro, José ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

Adolescence; CB1; CPP; MDMA; Mice

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABINOID 1 RECEPTOR;

ADOLESCENCE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; PLACE PREFERENCE; RECALL; REINFORCEMENT; WITHDRAWAL SYNDROME;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BENZOXAZINES; CALCIUM CHANNEL BLOCKERS; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXTINCTION, PSYCHOLOGICAL; HALLUCINOGENS; MALE; MICE; MORPHOLINES; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NAPHTHALENES; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; REINFORCEMENT SCHEDULE; SPATIAL BEHAVIOR; TIME FACTORS;

EID: 73649118466     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.10.019     Document Type: Article

References (50)

1. Braida D., Pozzi M., Cavallini R., and Sala M. Conditioned place preference induced by the cannabinoid agonist CP 55, 940: interaction with the opioid system. Neuroscience 104 (2001) 923-926
2. Braida D., Iosuè S., Pegorini S., and Sala M. 3, 4 Methylenedioxymethamphetamine-induced conditioned place preference (CPP) is mediated by endocannabinoid system. Pharmacol Res 51 (2005) 177-182
3. Chaperon F., Soubrié P., Puech A.J., and Thiébot M.H. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology 135 (1998) 324-332
4. Charmandari E., Kino T., Souvatzoglou E., and Chrousos G.P. Pediatric stress: hormonal mediators and human development. Horm Res 59 (2003) 161-179
5. Cheer J.F., Kendall D.A., and Marsden C.A. Cannabinoid receptors and reward in the rat: a conditioned place preference study. Psychopharmacology 151 (2000) 25-30
6. Colado M.I., O'Shea E., and Green A.R. Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology 173 (2004) 249-263
7. Daza-Losada M., Ribeiro Do Couto B., Manzanedo C., Aguilar M.A., Rodríguez-Arias M., and Miñarro J. Rewarding effects and reinstatement of MDMA-induced CPP in adolescent mice. Neuropsychopharmacology 32 (2007) 1750-1759
8. Degenhardt L., Hall W., and Lynskey M. The relationship between cannabis use and other substance use in the general population. Drug Alcohol Depend 64 (2001) 319-327
9. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., and Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34 (1988) 605-613
10. Diana M., Melis M., and Gessa G.L. Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur J Neurosci 10 (1998) 2825-2830
11. Ellgren M., Hurd Y.L., and Franck J. Amphetamine effects on dopamine levels and behavior following cannabinoid exposure during adolescence. Eur J Pharmacol 497 (2004) 205-213
12. Ellgren M., Spano S.M., and Hurd Y.L. Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology 32 (2007) 607-615
13. Ellgren M., Artmann A., Tkalych O., Gupta A., Hansen H.S., Hansen S.H., et al. Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. Eur Neuropsychopharmacol 18 (2008) 826-834
14. Escobedo I., O'shea E., Orio L., Sanchez V., Segura M., de la Torre R., et al. A comparative study on the acute and long-term effects of MDMA and 3, 4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after ip or striatal administration in mice. Br J Pharmacol 144 (2005) 231-241
15. Fattore L., Cossu G., Martellotta C.M., and Fratta W. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55, 212-2 in rats. Psychopharmacology 156 (2001) 410-416
16. Forget B., Hamon M., and Thiébot M.H. Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats. Psychopharmacology 181 (2005) 722-734
17. Gessa G.L., Melis M., Muntoni A.L., and Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 341 (1998) 39-44
18. Giuffrida A., Parsons L.H., Kerr T.M., Rodriguez de Fonseca F., Navarro M., and Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2 (1999) 358-363
19. Green A.R., Mechan A.O., Elliott J.M., O'shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3, 4 methylenedyoxymethamphetamine (MDMA, "Ecstasy"). Pharmacol Rev 55 (2003) 463-508
20. Informe anual 2008 del Observatorio Europeo de las Drogas: el estado del problema de las drogas en Europa. Plan Nacional sobre drogas. Ministerio de Sanidad y consumo.
21. Lepore M., Vorel S.R., Lowinson J., and Gardner E.L. Conditioned place preference induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward. Life Sci 56 (1995) 2073-2080
22. Lynskey M.T., Heath A.C., Bucholz K.K., Slutske W.S., Madden P.A., Nelson E.C., et al. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA 289 (2003) 427-433
23. Maldonado R., Valverde O., and Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29 (2006) 225-232
24. Mansbach R.S., Nicholson K.L., Martin B.R., and Balster R.L. Failure of Delta(9)-tetrahydrocannabinol and CP 55, 940 to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys. Behav Pharmacol 5 (1994) 219-225
25. Manzanedo C., Aguilar M.A., Rodríguez-Arias M., and Miñarro J. Effects of dopamine antagonists with different receptor blockade profiles on morphine-induced place preference in male mice. Behav Brain Res 121 (2001) 189-197
26. Manzanedo C., Aguilar M.A., Rodríguez-Arias M., Navarro M., and Miñarro J. Cannabinoid agonist-induced sensitisation to morphine place preference in mice. NeuroReport 15 (2004) 1373-1377
27. Marie-Claire C., Palminteri S., Romualdi P., and Noble F. Effects of the selective neurotensin antagonist SR 142948A on 3, 4-methylenedioxymethamphetamine-induced behaviours in mice. Neuropharmacology 54 (2008) 1107-1111
28. McGregor I.S., Issakidis C.N., and Prior G. Aversive effects of the synthetic cannabinoid CP 55, 940 in rats. Pharmacol Biochem Behav 53 (1996) 657-664
29. Melis M., Pistis M., Perra S., Muntoni A.L., Pillolla G., and Gessa G.L. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 24 (2004) 53-62
30. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
31. Nakazi M., Bauer U., Nickel T., Kathmann M., and Schlicker E. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol 361 (2000) 19-24
32. Navarro M., Carrera M.R., Fratta W., Valverde O., Cossu G., Fattore L., et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21 (2001) 5344-5350
33. Pandolfo P., Vendruscolo L.F., Sordi R., and Takahashi R.N. Cannabinoid-induced conditioned place preference in the spontaneously hypertensive rat-an animal model of attention deficit hyperactivity disorder. Psychopharmacology 205 (2009) 319-326
34. Parker L.A., and Gillies T. THC-induced place and taste aversions in Lewis and Sprague-Dawley rats. Behav Neurosci 109 (1995) 71-78
35. Parolaro D., and Rubino T. The role of endogenous cannabinoid system in drug addiction. Drug News Perspect 21 (2008) 149-157
36. Pistis M., Perra S., Pillolla G., Melis M., Muntoni A.L., and Gessa G.L. Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol Psychiatry 56 (2004) 86-94
37. Quinn H.R., Matsumoto I., Callaghan P.D., Long L.E., Arnold J.C., Gunasekaran N., et al. Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 33 (2008) 1113-1126
38. Rice D., and Barone Jr. S. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect 108 (2000) 511-533
39. Riegel A.C., and Lupica C.R. Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. J Neurosci 24 (2004) 11070-11078
40. Robbe D., Kopf M., Remaury A., Bockaert J., and Manzoni O.J. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci U S A 99 (2002) 8384-8388
41. Sañudo-Peña M.C., Tsou K., Delay E.R., Hohman A.G., Force M., and Walker J.M. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci Lett 223 (1997) 125-128
42. Schneider M., and Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28 (2003) 1760-1769
43. Schneider M., Drews E., and Koch M. Behavioral effects in adult rats of chronic prepubertal treatment with the cannabinoid receptor agonist WIN 55, 212-2. Behav Pharmacol 16 (2005) 447-454
44. Tanda G., Munzar P., and Goldberg S.R. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 3 (2000) 1073-1074
45. Valjent E., and Maldonado R. A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice. Psychopharmacology 147 (2000) 436-438
46. van Ree J.M., Slangen J.L., and de Wied D. Intravenous self-administration of drugs in rats. J Pharmacol Exp Ther 204 (1978) 547-557
47. Vlachou S., Nomikos G.G., and Panagis G. WIN 55, 212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation. Behav Brain Res 141 (2003) 215-222
48. Vlachou S., Nomikos G.G., and Panagis G. CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat. Psychopharmacology 179 (2005) 498-508
49. Zarrindast M.R., Nouri M., and Ahmadi S. Cannabinoid CB1 receptors of the dorsal hippocampus are important for induction of conditioned place preference (CPP) but do not change morphine CPP. Brain Res 1163 (2007) 130-137
50. Zimmermann P., Wittchen H.U., Waszak F., Nocon A., Höfler M., and Lieb R. Pathways into ecstasy use: the role of prior cannabis use and ecstasy availability. Drug Alcohol Depend 79 (2005) 331-341